CDBIO(688739)2025-02-25 08:20Financial Performance - Total revenue for 2024 was RMB 1,676,241,143.62, a decrease of 4.22% compared to RMB 1,750,103,088.24 in the previous year[4] - Net profit attributable to the parent company was RMB 333,585,103.98, down 28.40% from RMB 465,923,566.68 year-on-year[4] - Basic earnings per share decreased to RMB 0.81, a decline of 27.68% compared to RMB 1.12 in the previous year[4] - Operating profit fell to RMB 396,411,982.95, representing a decrease of 31.39% from RMB 577,795,555.86 in the prior year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 10,042,350,816.02, a slight decrease of 0.39% from RMB 10,081,359,085.19 at the beginning of the period[4] - Equity attributable to the parent company was RMB 9,553,231,500.82, down 0.48% from RMB 9,599,129,239.76 at the start of the period[4] Market and Competition - The decline in revenue was primarily due to intense competition in the domestic rabies vaccine market, despite increased sales of Japanese encephalitis inactivated vaccines and international rabies vaccines[6] R&D and Future Plans - Increased R&D expenses and a decline in investment valuations contributed to the drop in net profit and net profit after deducting non-recurring gains and losses[6] - The company plans to continue focusing on R&D and market expansion despite the current financial challenges[7] Return on Equity - The company’s weighted average return on equity decreased to 3.50%, down 1.34 percentage points from 4.84% in the previous year[4]